Related Experiment Video
Updated: Nov 29, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Regulating DSC2 Expression Affects the Proliferation and Apoptosis of Prostate Cancer Cells
1Department of Urology, Shanghai Pudong New Area People's Hospital, Shanghai 201200, People's Republic of China.
Background:
Prostate cancer threatens the life and health of men in China. Desmocollin-2 (DSC2) is a member of DSC family, abnormal expression of which can affect the invasion and metastasis of tumor cells. The aim of this study was to investigate the role of DSC2 in prostate cancer.
Materials And Methods:
Regulating DSC2 expression in prostate cancer cells was conducted with transfection. The expression of DSC2, apoptosis-related proteins, cell cycle-related proteins and E-cadherin (E-cad)/β-catenin pathway was detected by Western blot analysis. The proliferation, clone formation ability, migration, invasion and apoptosis of transfected cells were in turn detected by cell counting kit-8 (CCK-8) assay, clone formation assay, wound healing assay, transwell assay and flow cytometry analysis.
Results:
DSC2 expression was increased in prostate cancer cells compared with RWPE-1 cells. Inhibition of DSC2 promoted the proliferation, clone formation ability, migration and invasion while suppressed apoptosis of LNCaP cells and PC-3 cells. Inhibition of DSC2 affected the expression of apoptosis-related proteins and cell cycle-related proteins according to the changes of apoptosis and proliferation. Furthermore, inhibition of DSC2 up-regulated the expression of p-β-catenin and EGFR while down-regulated the expression of E-cad. DSC2 overexpression exerted the opposite effect of inhibition of DSC2 on LNCaP cells and PC-3 cells.
Conclusion:
DSC2 expression was increased in prostate cancer cells. In addition, inhibition of DSC2 promoted the proliferation, clone formation ability, migration and invasion while suppressed apoptosis of LNCaP cells and PC-3 cells, which provided the fundamental basis for treatment of prostate cancer.
Insights
Desmocollin-2 (DSC2) is elevated in prostate cancer. Inhibiting DSC2 boosts cancer cell growth and spread while reducing cell death, offering potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Prostate cancer is a significant health concern for men.
- Desmocollin-2 (DSC2), a member of the DSC family, is implicated in tumor cell invasion and metastasis.
Purpose of the Study:
- To investigate the role of DSC2 in prostate cancer progression.
Main Methods:
- DSC2 expression was manipulated in prostate cancer cell lines.
- Western blot analysis was used to assess protein expression.
- Cell proliferation, clone formation, migration, invasion, and apoptosis were evaluated using various assays.
Main Results:
- DSC2 expression was higher in prostate cancer cells than in normal cells.
- Inhibiting DSC2 increased proliferation, migration, and invasion while decreasing apoptosis.
- DSC2 inhibition altered apoptosis and cell cycle-related protein expression, affecting the E-cadherin/β-catenin pathway.
Conclusions:
- DSC2 is upregulated in prostate cancer.
- Inhibiting DSC2 promotes prostate cancer cell proliferation and metastasis, suggesting DSC2 as a potential therapeutic target.
Related Concept Videos
Abnormal Proliferation
Inhibition of Cdk Activity
Negative Regulator Molecules
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

